Navigation Links
Regeneron Reports Third Quarter 2009 Financial and Operating Results
Date:11/3/2009

compensation expense related to employee stock option and restricted stock awards of $7.5 million in the third quarter of 2009 and $22.6 million for the first nine months of 2009, compared with $8.2 million and $24.7 million, respectively, for the same periods of 2008.

Research and development (R&D) expenses increased to $105.4 million in the third quarter of 2009 from $72.1 million in the comparable quarter of 2008, and to $280.0 million in the first nine months of 2009 from $200.3 million in the same period of 2008. In the third quarter and first nine months of 2009, the Company incurred higher R&D costs primarily related to additional R&D headcount, clinical development costs for ARCALYST, VEGF Trap-Eye, and monoclonal antibodies, research and preclinical development costs associated with the antibody programs, and facility-related costs to support expanded R&D activities.

Selling, general, and administrative (SG&A) expenses increased to $12.8 million in the third quarter of 2009 from $11.1 million in the comparable quarter of 2008, and to $35.9 million in the first nine months of 2009 from $35.7 million in the same period of 2008. In the third quarter and for the first nine months of 2009, the Company incurred higher compensation and facility-related expenses due primarily to increases in administrative headcount to support the expanded research and development activities, higher patent-related costs, and higher expenses related to ARCALYST® (rilonacept), partially offset by lower market research costs related to various programs and a decrease in recruitment costs for administrative headcount.

Other Income and Expense

Investment income decreased to $0.9 million in the third quarter of 2009 from $3.7 million in the comparable quarter of 2008 and to $3.9 million in the first nine months of 2009 compared to $15.5 million in the first nine months of 2008. The decrease in investme
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)...  Varian Medical Systems (NYSE: VAR ) ... fourth quarter of fiscal year 2014 following the close ... news release will be followed by a teleconference available ... news release and a link to the conference call ... www.varian.com/investor .  To access the teleconference call and ...
(Date:10/1/2014)... , Oct. 1, 2014  Express Scripts (NASDAQ: ... available 2015 Express Scripts Medicare ® Prescription Drug ... featuring Walgreens (NYSE: WAG ) (NASDAQ: ... choice and clinical support  for their Medicare dollars. ... Medicare Value or Choice plans ...
(Date:10/1/2014)... 2014   Royal Philips (NYSE: ... eCareCoordinator and eCareCompanion telehealth applications have received 510(k) ... (FDA). A part of Philips Hospital to Home,s ... eCareCompanion are focused on patient care within the ... be available through the cloud-based digital health platform, ...
Breaking Medicine Technology:Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4
... SYDNEY, Australia, Aug. 17 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; ... Phase 3,clinical trial of Bronchitol for the treatment ... efficacy data from the trial is expected to ... trial commenced its dosing phase in,April 2007, reached ...
... Activity, VOORHEES, N.J., Aug. 14 ... and mortality in recipients of hematopoietic,stem cell ... are,serious and range from gastrointestinal disease to ... order to prevent CMV infection and reduce ...
Cached Medicine Technology:Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment 2CMV Disease in Stem Cell Transplantation: Prevention and Drug Resistance 2
(Date:10/1/2014)... encourages people to keep their "eyes on the prize" ... When walking, staying focused on a specific target ahead ... help people walk there faster, psychology researchers have found. ... looking around the environment naturally, offers a new strategy ... less interested in exercise if physical activity seems daunting, ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new ... insurance prices for smokers. , Smoking will always have ... quotes is the best method to find affordable coverage. ... who need coverage. , Whole life insurance premiums ... policy. Since the coverage is permanent, the initial ...
(Date:10/1/2014)... 2014 Join the more than 80 golfers ... Center’s first ever charity golf tournament to benefit Project HEAL, ... disorders who cannot afford treatment. The tournament will be held ... Mo. , The day-long event starts with 10:30 a.m. ... award dinner will begin at 5 p.m. and will include ...
(Date:10/1/2014)... October 01, 2014 Diet Doc understands that ... to lose weight and their dieting attempts could be easily ... Including hormone diet treatments into their programs as ... to see fast and effective weight loss results, it also ... healthy habits to maintain their weight for the future. , ...
(Date:10/1/2014)... Bahir Dar, Ethiopia, at the occasion of the ... some 150 African and international leishmaniasis experts, results ... and efficacy monitoring plan, carried out by ... Uganda, and Ethiopia, were presented to key decision ... treatment of kala-azar with the combination of Sodium ...
Breaking Medicine News(10 mins):Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2
... simple diagnostic modality can help predict the outcome of ... It can predict which patient would benefit from the ... valuable study can be found in the latest issue ... physicians identify factors that cause specific symptoms by demonstrating ...
... prescription drugs in the filtered and recycled wastewater at ... dangerous effects this water might have in the future. ... antibiotics, antipsychotics, birth-control hormones, Viagra and Valium have been ... the wastewater is because people flush them down their ...
... Boston, a surgery was conducted on a baby inside the womb. ... the womb. // She was discharged on Friday after the successful ... a heart defect called hypoplastic left heart syndrome (HLHS) inside the ... in the developing fetus on November 7, 2005. ,She ...
... services in a hospital at Brisbane a patient had to ... was attacked and was in serious condition, attention could not ... Caboolture Hospital, where emergency services are scarce due to shortage ... presently operational from 8am to 6pm every day. ...
... announced that it intends to fast track its inhaled insulin ... Food and Drug Administration // and the European Commission ... Sanofi-Aventis and Nektar Therapeutics. ,It is a relatively ... or syringes are needed. "Until today, patients with diabetes who ...
... successfully reached the Vinson Massif summit, one of Antarctica's ... and was successfully completed on January 19th after eight ... was a strong, healthy athlete who was later diagnosed ... of the disease he lost 80 pounds and his ...
Cached Medicine News:Health News:SPECT Can Help Predict Treatment Outcome In Patients With Low Back Pain 2Health News:Medications Detected In Recycled Water In Los Angeles 2Health News:Baby Underwent A Heart Surgery Inside The Womb 2Health News:Crohn's Patient Robert Hill’s greatest achievemen 2
... very attractive price. ,The following adjustments can be made: , ... 5 1/2" (98 to 135mm), Nose bridge height 0-14mm, ... to 40mm on each side (48mm to 80mm total both ... to 0 to 135 , right - 45 to 180 ...
... Sterile Bad-Parker blades offer the superior ... steel technology, plus the exclusive Rib-Back ... strength. Brad-Parker brand producer offer the ... and disposable scalpels. Every blade is ...
BD Beaver Chondroplastic blade, sharp on two sides, curved, sterile...
RM-1970 Mucotome ergonomic design with E-Type coupling, designed for mucosal repair surgery....
Medicine Products: